ReviewInternational journal of women's health2023
Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians.
Review in International journal of women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- VagiBIOM Lactobacillus suppository improves vaginal health index in perimenopausal women with bacterial vaginosis: a randomized control trial.Scientific reports · 2024Trial
- Prevalence, Risk Factors, and Co-Occurrence ofMicroorganisms · 2026Article
- Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Effect of bacterial vaginosis on induced labour in the third trimester of pregnancy: a retrospective cohort study.BMC pregnancy and childbirth · 2026Article
- Review
- Association of culture-detected vaginal microbiota and body composition parameters with gestational diabetes outcomes.Frontiers in cellular and infection microbiology · 2026Observational
- Adjunctive probiotic therapy enhances metronidazole efficacy in bacterial vaginitis: a clinical trial on Iranian women.GMS hygiene and infection control · 2026Article
- Targeting vaginal dysbiosis: prospects for the application of live biotherapeutics products.Frontiers in microbiology · 2026Review
- Natural Molecules, Nutraceuticals, and Engineered Nanosystems: A Comprehensive Strategy for CombatingMicroorganisms · 2025Review
- Endolysin selectively kills Gardnerella ex vivo in vaginal samples from women with bacterial vaginosis.NPJ biofilms and microbiomes · 2025Article
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- Association between changes in genital immune markers and vaginal microbiome transitions in bacterial vaginosis.Scientific reports · 2025Article
- Article
- Non-linear association between serum vitamin D and bacterial vaginosis in U.S. women: analysis from NHANES 2001-2004.Frontiers in nutrition · 2025Article
- Evaluation of Metronidazole Resistance of Vaginal Swab Isolates from South African Women Treated for Bacterial Vaginosis.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Bacterial vaginosis (BV) is the most common vaginal infection worldwide. It is associated with an increased risk of acquisition of HIV and other sexually transmitted infections (STIs) as well as pelvic inflammatory disease and adverse birth outcomes. During BV, a polymicrobial biofilm forms on the surface of the vaginal mucosa. However, the exact etiology of BV remains controversial which has impeded significant advances in diagnosis, treatment, and prevention. Despite 30-day cure rates approaching 80% in BV-infected women treated with 7 days of oral metronidazole, recurrence within 12 months is common. This article provides a current review of the epidemiology, pathogenesis, diagnosis, and treatment of recurrent BV for practicing clinicians who commonly see women with this recurrent vaginal infection. Regarding management, we focus primarily on antimicrobial measures that may be effective. Future areas of research in this field are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.